Cargando…
An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
Inhaled antibiotics such as colistin and ciprofloxacin are increasingly used to treat bacterial lung infections in cystic fibrosis patients. In this study, we established and validated a new HPLC-MS/MS method that could simultaneously detect drug concentrations of ciprofloxacin, colistin and ivacaft...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Xi'an Jiaotong University
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740159/ https://www.ncbi.nlm.nih.gov/pubmed/35028178 http://dx.doi.org/10.1016/j.jpha.2021.02.004 |
_version_ | 1784629253812256768 |
---|---|
author | Yuan, Huiya Yu, Shihui Chai, Guihong Liu, Junting Zhou, Qi (Tony) |
author_facet | Yuan, Huiya Yu, Shihui Chai, Guihong Liu, Junting Zhou, Qi (Tony) |
author_sort | Yuan, Huiya |
collection | PubMed |
description | Inhaled antibiotics such as colistin and ciprofloxacin are increasingly used to treat bacterial lung infections in cystic fibrosis patients. In this study, we established and validated a new HPLC-MS/MS method that could simultaneously detect drug concentrations of ciprofloxacin, colistin and ivacaftor in rat plasma, human epithelial cell lysate, cell culture medium, and drug transport media. An aliquot of 200 μL drug-containing rat plasma or cell culture medium was treated with 600 μL of extraction solution (acetonitrile containing 0.1% formic acid and 0.2% trifluoroacetic acid (TFA)). The addition of 0.2% TFA helped to break the drug-protein bonds. Moreover, the addition of 0.1% formic acid to the transport medium and cell lysate samples could significantly improve the response and reproducibility. After vortexing and centrifuging, the sample components were analyzed by HPLC-MS/MS. The multiple reaction monitoring mode was used to detect the following transitions: 585.5–101.1 (colistin A), 578.5–101.1 (colistin B), 393.2–337.2 (ivacaftor), 332.2–314.2 (ciprofloxacin), 602.3–101.1 (polymyxin B1 as internal standard (IS)) and 595.4–101.1 (polymyxin B2 as IS). The running time of a single sample was only 6 min, making this a time-efficient method. Linear correlations were found for colistin A at 0.029–5.82 μg/mL, colistin B at 0.016–3.14 μg/mL, ivacaftor at 0.05–10.0 μg/mL, and ciprofloxacin at 0.043–8.58 μg/mL. Accuracy, precision, and stability of the method were within the acceptable range. This method would be highly useful for research on cytotoxicity, animal pharmacokinetics, and in vitro drug delivery. |
format | Online Article Text |
id | pubmed-8740159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Xi'an Jiaotong University |
record_format | MEDLINE/PubMed |
spelling | pubmed-87401592022-01-12 An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin Yuan, Huiya Yu, Shihui Chai, Guihong Liu, Junting Zhou, Qi (Tony) J Pharm Anal Original Article Inhaled antibiotics such as colistin and ciprofloxacin are increasingly used to treat bacterial lung infections in cystic fibrosis patients. In this study, we established and validated a new HPLC-MS/MS method that could simultaneously detect drug concentrations of ciprofloxacin, colistin and ivacaftor in rat plasma, human epithelial cell lysate, cell culture medium, and drug transport media. An aliquot of 200 μL drug-containing rat plasma or cell culture medium was treated with 600 μL of extraction solution (acetonitrile containing 0.1% formic acid and 0.2% trifluoroacetic acid (TFA)). The addition of 0.2% TFA helped to break the drug-protein bonds. Moreover, the addition of 0.1% formic acid to the transport medium and cell lysate samples could significantly improve the response and reproducibility. After vortexing and centrifuging, the sample components were analyzed by HPLC-MS/MS. The multiple reaction monitoring mode was used to detect the following transitions: 585.5–101.1 (colistin A), 578.5–101.1 (colistin B), 393.2–337.2 (ivacaftor), 332.2–314.2 (ciprofloxacin), 602.3–101.1 (polymyxin B1 as internal standard (IS)) and 595.4–101.1 (polymyxin B2 as IS). The running time of a single sample was only 6 min, making this a time-efficient method. Linear correlations were found for colistin A at 0.029–5.82 μg/mL, colistin B at 0.016–3.14 μg/mL, ivacaftor at 0.05–10.0 μg/mL, and ciprofloxacin at 0.043–8.58 μg/mL. Accuracy, precision, and stability of the method were within the acceptable range. This method would be highly useful for research on cytotoxicity, animal pharmacokinetics, and in vitro drug delivery. Xi'an Jiaotong University 2021-12 2021-02-28 /pmc/articles/PMC8740159/ /pubmed/35028178 http://dx.doi.org/10.1016/j.jpha.2021.02.004 Text en © 2021 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Yuan, Huiya Yu, Shihui Chai, Guihong Liu, Junting Zhou, Qi (Tony) An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin |
title | An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin |
title_full | An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin |
title_fullStr | An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin |
title_full_unstemmed | An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin |
title_short | An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin |
title_sort | lc-ms/ms method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740159/ https://www.ncbi.nlm.nih.gov/pubmed/35028178 http://dx.doi.org/10.1016/j.jpha.2021.02.004 |
work_keys_str_mv | AT yuanhuiya anlcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin AT yushihui anlcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin AT chaiguihong anlcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin AT liujunting anlcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin AT zhouqitony anlcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin AT yuanhuiya lcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin AT yushihui lcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin AT chaiguihong lcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin AT liujunting lcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin AT zhouqitony lcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin |